ArticleEuropean radiology experimental2026
Pulmonary arterial flow alterations in systemic lupus erythematosus on 4D flow CMR: a case-control study.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePulmonary arterial hypertension is a severe complication of systemic lupus erythematosus (SLE). Current screening methods often miss early vascular changes. This study aimed to characterize subclinical pulmonary hemodynamic alterations in SLE patients without known pulmonary arterial hypertension using four-dimensional (4D) flow cardiovascular magnetic resonance (CMR) and to investigate their association with left ventricular diastolic function. MATERIALS AND
methodsTwenty-five SLE patients without known pulmonary arterial hypertension and 25 age-matched healthy controls were enrolled. All participants underwent 3-T 4D flow CMR to quantify hemodynamic parameters, including wall shear stress (WSS), flow volume, and relative pressure in the pulmonary arteries. SLE patients were further stratified based on echocardiographic assessment of diastolic function to analyze hemodynamic coupling.
resultsCompared to controls, SLE patients exhibited significantly lower maximum WSS in the main pulmonary artery (0.29 versus 0.33 Pa, p = 0.040) and asymmetric flow redistribution, characterized by higher relative pressure in the left pulmonary artery (0.54 versus 0.30 mmHg, p = 0.008) and increased flow rate in the right pulmonary artery (3.51 versus 2.90 L/min, p = 0.015). Qualitative analysis revealed vortical flow patterns in SLE patients. Subgroup analysis demonstrated that the reduction in WSS was primarily driven by patients with diastolic dysfunction (p = 0.006 versus controls).
conclusionSLE patients without pulmonary arterial hypertension exhibit distinct subclinical pulmonary hemodynamic alterations, including lower WSS and flow asymmetry. These alterations are intimately coupled with left ventricular diastolic dysfunction, suggesting that 4D flow CMR serves as a sensitive noninvasive tool for early risk stratification in this population. RELEVANCE STATEMENT: 4D flow CMR identifies subclinical pulmonary hemodynamic alterations coupled with diastolic dysfunction in SLE patients, serving as a sensitive noninvasive tool for early risk stratification before irreversible vascular remodeling occurs. KEY POINTS: SLE patients without known pulmonary arterial hypertension show early pulmonary blood flow changes. 4D flow CMR detected asymmetric pulmonary flow redistribution in SLE patients. SLE patients exhibited altered left atrial function despite normal ventricles. Pulmonary flow changes correlated with left atrial remodeling in SLE. 4D flow CMR detects subclinical pulmonary hemodynamic differences in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.